ArticleScientific reports2026
Pravastatin combined with fibrin sealant-embedded BMSCs enhances recovery in steroid-induced avascular necrosis of the femoral head.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-induced avascular necrosis of the femoral head (SANFH) significantly impairs patients' quality of life, with long-term steroid use being a major contributing factor. The pathogenesis of SANFH remains complex and poorly understood. Bone marrow mesenchymal stem cells (BMSCs) possess multidirectional differentiation potential and are crucial for bone repair and regeneration, yet their precise mechanisms in SANFH treatment are not fully elucidated. In this study, 48 rabbits with early-stage SANFH were randomly assigned to four groups: control (Group A), core decompression (Group B), BMSCs embedded in fibrin sealant (FS) after decompression (Group C), and pravastatin administration combined with BMSCs in FS post-decompression (Group D). Blood lipid levels were monitored throughout the experiment, and femoral heads were assessed via MRI, HE staining, and VEGF immunohistochemical staining. Group C demonstrated reduced femoral head necrosis and increased new bone formation compared to the control. Group D showed significantly lower serum lipid content and femoral head necrosis than other groups, with HE staining revealing fewer empty lacunae and increased trabecular bone density. Additionally, VEGF expression was markedly elevated in Group D. These findings indicate that BMSCs embedded in biomaterials enhance the therapeutic efficacy for early SANFH, and the combination with pravastatin significantly improves outcomes, suggesting a promising new approach for clinical management of femoral head necrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.